• Go to navigation
  • Go to content
AstraZeneca Young Minds

You are here

  • Home
  • 2003 Winners
  • United States/Schizophrenia Category

Astrazeneca global websites

  • AstraZeneca Websites

Main navigation

  • Home
  • 2006 Winners
  • 2005 Winners
  • 2004 Winners
  • 2003 Winners
    • International/Bipolar Disorder Category
    • United States/Bipolar Disorder Category
    • International/Schizophrenia Category
    • United States/Schizophrenia Category
  • How to Apply
  • Proposal Evaluation
  • Steering Committee
  • Calendar
  • Sitemap

United States / Schizophrenia Category

Title of Winning Proposal: Vulnerability Indicators and Potential Markers of Abnormal Fetal Development in Schizophrenia

Michael T. Compton

Michael T. Compton, M.D., M.P.H.
Assistant Professor
Dept. of Psychiatry & Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Michael T. Compton, M.D., M.P.H. is Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine, where he works on an inpatient psychiatric unit at Grady Memorial Hospital. He has a secondary appointment in the Department of Family and Preventive Medicine. Dr. Compton completed undergraduate education at Mary Washington College in Fredericksburg, Virginia, majoring in both

biology and religion. He then attended the University of Virginia School of Medicine in Charlottesville, Virginia. After training in psychiatry at Emory University in Atlanta, he completed Emory's new two-year Postdoctoral Fellowship in Community Psychiatry / Public Health. He also completed residency training in preventive medicine. Dr. Compton's primary research interest is the early course of schizophrenia, and he plans to pursue a career in prevention-oriented schizophrenia research. He hopes to soon receive funding from the National Institute of Mental Health for a career development award to study the determinants and consequences of the duration of initial untreated psychosis. He is also very interested schizophrenia endophenotypes / vulnerability indicators. Other interests include substance abuse in the early course of schizophrenia, treatment adherence, antipsychotic-induced hyperprolactinemia and sexual side effects, and adverse health behaviors among those with severe mental illnesses.

Return to 2003 Winners
  • Advanced search

Page tools

  • Print
  • Bookmark this page
AstraZeneca

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2009